[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrointestinal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrointestinal-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,51,80,113,140,166,187],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100588376","exclude-or-expose-in-irritable-bowel-syndrome-what-works-for-whom-and-how-100588376",false,"NCT06940596","Exclude or Expose in Irritable Bowel Syndrome: What Works for Whom and How?","Exclude or Expose in Irritable Bowel Syndrome: What Works for Whom, and How? A Randomized Controlled Trial of Internet-Delivered FODMAP Diet Versus Exposure-Based Cognitive Behavioral Therapy","Inclusion Criteria: Each participant must meet all of the following criteria to be enrolled in this trial:\n\n* Living in Australia or the United States\n* Aged 18 years or older\n* Body Mass Index (BMI) \\[Equation\\]18.5kg\u002Fm2 and \\[Equation\\] 34.9kg\u002Fm2\n* Diagnosed with IBS by a General Practitioner, Family Physician, or Gastroenterologist, or Advanced Specialist Dietitian\n* Currently fulfill Rome IV criteria for IBS\n* Symptomatic at the time of recruitment (IBS-SSS \\> 175)\n* Access to a computer and internet\n* Sufficient English language and computer skills to complete a text-based online treatment\n* Willing to make dietary or behavioral changes in line with the allocated treatment program\n* Ability to provide informed consent\n\nExclusion Criteria:Patients meeting any of the following criteria will be excluded from the trial:\n\n* Presence or known history of other GI disease (e.g. coeliac disease, Inflammatory Bowel Disease) or history of gastrointestinal cancer\n* History of major gastrointestinal surgery (not appendectomy, cholecystectomy or hemorrhoidectomy)\n* Individuals who report alarm symptoms (e.g., blood in stool, recent unexplained\u002Funintentional weight loss \\>5% body weight, a recent change in bowel habits if \\>50 years, family history of gastrointestinal cancer or gastrointestinal diseases, large volumes of diarrhea occurring at night, fever associated with gut symptoms, recurrent vomiting, persistent unexplained iron deficiency) will be excluded if appropriate medical investigations have not been conducted, unless written medical approval is provided from a general practitioner, family physical, or gastroenterologist.\n* Diagnosis of major disease that could explain current gastrointestinal symptoms such as severe diabetic, cardiac, liver, neurological, neuropathy disease\n* History or current diagnosis of psychotic disorder or bipolar disorder\n* Current diagnosis of substance abuse disorder or major depressive disorder or active suicidal ideation\n* History or current diagnosis of an eating disorder\n* Current enteral\u002Fparenteral feeding or use of supplemental feeds (e.g. Ensure)\n* Pregnant or lactating or planning to become pregnant during the 12-week intervention period\n* Commenced or change in dose of antibiotics and medications that potentially affect the gastrointestinal transit (e.g. anti-diarrheals and laxatives) in the 3 months preceding study commencement.\n* Commenced taking or changed dose of probiotics, prebiotics, fibre supplements and digestive enzymes in the 3 months preceding study commencement\n* Commenced or change dose in psychotropic medication in the 3 months preceding study commencement\n* Are currently undertaking behavioral therapy for IBS (including cognitive behavioral therapy, CBT), or have undertaken clinician-delivered behavioral therapy for the treatment of IBS\n* Are currently undertaking or have undertaken a dietitian-prescribed and delivered restrictive diet for IBS (e.g., FODMAP diet).","ALL","18 Years",{"count":19,"type":20},235,"ESTIMATED","INTERVENTIONAL",[23],"NA","This research project will assess how two treatments for irritable bowel syndrome (one dietary and one behavioral) work and for whom. This will be done by assessing moderators (what treatment works for who and in what context) and mediators (how treatment works). Investigators will also assess how the diet and behavioral treatments affect IBS symptoms during treatment. Participants will be randomized to either: i. A FODMAP diet online program that focuses on modifying the consumption of foods high or moderate in fermentable carbohydrates (FODMAPS) to manage IBS symptoms. or, ii. An Exposure-based Cognitive Behavioral Therapy (E-CBT) online program for IBS that focuses on changing symptom-related behaviors which are known to worsen IBS symptoms.",[26,27,28],"Irritable Bowel Syndrome (IBS)","Intestinal Diseases","Gastrointestinal Disease",[30,31,32,33,34,35,27,36,37],"Irritable Bowel Syndrome","FODMAP Diet","Behavior Therapy","Gastrointestinal Diseases","Cognitive Behavioral Therapy","Exposure Based Cognitive Behavioral Therapy","Digestive System Diseases","Low FODMAP Diet","RECRUITING","2026-04-29",{"date":41,"type":42},"2026-05-06","ACTUAL",{"date":44,"type":42},"2025-05-22",{"date":46,"type":20},"2028-04",{"name":48,"class":49},"University of Melbourne","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":50},"100583561","elemental-028-extra-case-studies-100583561","NCT06877923","Elemental 028 Extra Case Studies","Evaluating the Tolerance, Compliance and Acceptability of a Nutritionally Complete Amino Acid-based Nutritional Supplement for the Dietary Management of Conditions With a Severe Impairment of the Gastrointestinal Tract in Children and Adults: a Case Study Series","E028E","Inclusion Criteria:\n\n* Male or female\n* Over 3 years of age\n* Requiring an elemental feed (at least 30% of total energy requirements)\n* Written or electronic informed consent from patient, and\u002For from parent\u002Fcaregiver if applicable\n\nExclusion Criteria:\n\n* Pregnant or lactating\n* Requiring parenteral nutrition\n* Major hepatic or renal dysfunction\n* Participation in other studies within 1 month prior to entry of this study\n* Investigator concern around willingness\u002Fability of patient or parent\u002Fcaregiver to comply with protocol requirements","3 Years",{"count":61,"type":20},30,[23],"Elemental 028 Extra is a nutritionally complete ACBS approved amino acid-based (elemental) feed designed to provide adequate daily amounts of both macronutrients and micronutrients when used as a sole source of nutrition and to support patients with severe impairment of the gastrointestinal tract who may require an elemental diet. An upgraded formulation of Elemental 028 Extra with an increased energy, protein content micronutrient profile has been developed to better meet the nutritional requirements of patients.\n\nThis series of case-studies aims to evaluate the acceptability, compliance, and gastrointestinal tolerance of the upgraded formulation of Elemental 028 Extra, in 30 adult and paediatric patients (15 powder and 15 liquid), with conditions where there is a severe impairment of the gastrointestinal tract, such as inflammatory bowel disease, short bowel syndrome, intractable malabsorption, allergic disease, and neurodegenerative diseases, and an elemental feed is required. The case study will last 29 days in total, including a 1-day baseline period followed by a 28-day intervention period. The case studies will be conducted across multiple centres in the UK, to meet the UK ACBS and GMS requirements for acceptability studies.",[28,65,66,67,68,69],"Inflammatory Bowel Disease (IBD)","Short Bowel","Malabsorption","Allergies","Neurodegenerative Disorders","2026-02-13",{"date":72,"type":42},"2026-02-17",{"date":74,"type":42},"2025-05-01",{"date":76,"type":20},"2027-02",{"name":78,"class":79},"Nutricia UK Ltd","INDUSTRY",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":50},"100621094","long-term-health-outcomes-of-screen-detected-and-potential-celiac-disease-patients-100621094","NCT07366151","Long-term Health Outcomes of Screen Detected and Potential Celiac Disease Patients","The Impact of Active Screening on the Long-term Health of Celiac Disease Patients and the Natural Course of Potential Untreated or Treated Celiac Disease","Inclusion Criteria:\n\n* Finnish citizenship and current residence in Finland\n\nExclusion Criteria:\n\n* Age \\\u003C18 years",{"count":88,"type":20},250,"OBSERVATIONAL","The primary aim of this project is to investigate how active screening and the timing of diagnosis affect the long-term health outcomes of patients with celiac disease. Additionally, the study seeks to clarify the natural course of so-called potential celiac disease. A key focus is also placed on assessing adherence to a gluten-free diet among screen-detected and, if initiated, potential celiac disease patients, their satisfaction with the diagnosis, and the diet's impact on general health and quality of life.",[92,27,28,36,93],"Malabsorption Syndromes","Celiac Disease",[95,96,97,98,99,100,101,102],"Celiac disease","Potential celiac disease","Gluten-free diet","Screen detected","Long-term health","Quality of life","Symptoms","Asymptomatic","NOT_YET_RECRUITING","2026-01-23",{"date":106,"type":42},"2026-01-26",{"date":108,"type":20},"2026-03-01",{"date":110,"type":20},"2034-12",{"name":112,"class":49},"Tampere University Hospital",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":16,"minAge":121,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":50},"100601739","phase-3-a-study-to-evaluate-safety-and-efficacy-of-pbkm2502-100601739","NCT07114406","A Study to Evaluate Safety and Efficacy of PBK_M2502","A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK_M2502","Inclusion Criteria:\n\n* Patients who is informed and give a consent in voluntary\n* Patients who is scheduled a esophagogastroduodenoscopy and colonoscopy\n* BMI 19≤and\\\u003C30\n\nExclusion Criteria:\n\n* Patients who participate in other interventional study or had participated within 30 days before screening\n* Pregnant or breast-feeding women who do not want to stop breast-feeding\n* Uncontrolled hypertension\n* Uncontrolled diabetes\n* Fluid or electrolyte (Na, K, Ca, Mg, chloride, bicarbonate) disturbance\n* HIV infection and\u002For chronic hepatitis B or C\n* Patients who has a difficulty to participate because of severe nausea or vomiting\n* History of colon surgery and abdominal surgery within 6 month; need an emergency surgery",true,"19 Years",{"count":123,"type":20},110,[125],"PHASE3","This clinical trial was prospective, randomized, single-blind, 3-treatment arm, parallel treatment group, and active-controlled. , Multi-center, Phase 3 confirmatory clinical trial.",[128,129,28,130],"Intestinal Disease","Colonic Diseases","Digestive System Disease","2025-08-03",{"date":133,"type":42},"2025-08-11",{"date":135,"type":20},"2025-08",{"date":137,"type":20},"2026-11",{"name":139,"class":79},"Pharmbio Korea Co., Ltd.",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":50},"100593158","application-of-remimazolam-combined-with-esketamine-in-painless-gastroscopy-and-colonoscopy-in-elderly-patients-100593158","NCT07002801","Application of Remimazolam Combined With Esketamine in Painless Gastroscopy and Colonoscopy in Elderly Patients","Inclusion Criteria:\n\n1. Patients undergoing painless gastroenteroscopy in outpatient clinics;\n2. aged 65 years and above;\n3. American Society of Anesthesiologists (ASA) grades I - III.\n\nExclusion Criteria:\n\n1. Patients with abnormal liver or kidney function;\n2. known respiratory or endocrine diseases;\n3. Patients with uncontrolled hypertension and NYHA classification Ⅲ-Ⅳ;\n4. Taking monoamine oxidase inhibitors, sedatives, analgesics, hypnotics, antipsychotics, antiemetics or antidepressants;\n5. Addiction to tobacco and alcohol;\n6. Patients allergic to the investigational drug;\n7. expected difficult airway;\n8. Body mass index (BMI) \\>35kg\u002Fm\\^2;\n9. Have participated in other clinical trials within the past three months;\n10. Patients with psychosocial illness or cognitive dysfunction and inability to cooperate or communicate.","65 Years",{"count":148,"type":20},280,[23],"The objective of this clinical trial is to assess the feasibility of the remimazolam combined with esketamine OFA (opioid-free anesthesia) protocol for painless gastroscopy and colonoscopy in elderly patients and to determine if it is non-inferior to the traditional OA (opioid-containing anesthesia) protocol. The main questions it aims to answer are:\n\n* Is the remimazolam combined with esketamine protocol feasible for painless gastroscopy and colonoscopy in elderly patients?\n* Is the OFA protocol superior to the OA protocol?\n\nParticipants will:\n\n* During anesthesia induction, the experimental group will receive remimazolam combined with esketamine for anesthesia, while the control group will receive remimazolam combined with remifentanil.\n* Record respiratory and circulatory indicators and adverse reaction times.",[28],[153,154,155,156],"remimazolam","esketamine","painless gastroscopy and colonoscopy","success rate of calming down","2025-05-26",{"date":159,"type":42},"2025-06-04",{"date":161,"type":42},"2025-03-14",{"date":163,"type":20},"2028-01",{"name":165,"class":49},"Harbin Medical University",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100550131","long-term-outcomes-of-duodenal-adenocarcinoma-from-a-large-cohort-100550131","NCT06443086","Long-term Outcomes of Duodenal Adenocarcinoma From a Large Cohort","Long-term Survival Outcomes of Duodenal Adenocarcinoma: a Cohort Study With 15-year Single-center Experience","Inclusion criteria:\n\n(1) histologically confirmed non-ampulla DA;\n\nExclusion criteria:\n\n1. had other gastrointestinal cancer;\n2. had incomplete medical records, or lost follow-up shortly after diagnosis;\n3. refused clinical data collection.","80 Years",{"count":175,"type":20},400,"The investigators will conducted a hospital-based cohort study in our 15-year experience with DA aimed at investigating the long-term outcomes of the patients with DA, along with analyzing the impact of the tumor characteristics, operations and adjuvant therapy on survival outcomes.",[28],"2024-06-03",{"date":180,"type":42},"2024-06-05",{"date":182,"type":20},"2024-06-15",{"date":184,"type":20},"2024-12-30",{"name":186,"class":49},"Nanfang Hospital, Southern Medical University",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":198,"conditions":199,"keywords":215,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":229},"100435367","spanish-series-of-patients-treated-with-the-radionuclide-lutetium177-100435367","NCT04949282","Spanish Series of Patients Treated With the Radionuclide Lutetium177","SEPTRALU, Spanish Series of Patients Treated With the Radionuclide Lutetium177","SEPTRALU","Inclusion Criteria:\n\n* Written informed consent must be obtained prior to any data collection.\n* Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour\n* Aged ≥18 years.\n\nExclusion Criteria:\n\n* None","100 Years",{"count":197,"type":20},5000,"This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.",[200,201,202,203,204,205,206,207,208,209,210,211,212,36,28,27,213,214],"Neuroendocrine Tumors","Intestinal Neoplasms","Pancreatic Neoplasms","Stomach Neoplasms","Neuroectodermal Tumors","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms","Neoplasms, Nerve Tissue","Gastrointestinal Neoplasms","Digestive System Neoplasms","Neoplasms by Site","Endocrine Gland Neoplasms","Pancreatic Disease","Endocrine System Diseases",[216,217,218,219],"GEP-NET","Gastro-Entero-Pancreatic Neuroendocrine Tumour","Luthatera","Somatostatin receptor positive tumour","2022-12-22",{"date":222,"type":42},"2022-12-23",{"date":224,"type":42},"2021-05-10",{"date":226,"type":20},"2035-12-31",{"name":228,"class":49},"Sociedad Española de Medicina Nuclear e Imagen Molecular",20]